---
title: 'Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine,
  cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real
  world cohort'
date: '2024-09-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39301763/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240921200343&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Immuno-chemotherapy in patients with BTC was feasible,
  effective and safe in a real-life scenario. Our results were comparable to the phase
  3 clinical trial results (TOPAZ-1). Reduced efficacy was noted in patients with
  GB-CA and/or a reduced performance status that warrants further ...'
disable_comments: true
---
CONCLUSIONS: Immuno-chemotherapy in patients with BTC was feasible, effective and safe in a real-life scenario. Our results were comparable to the phase 3 clinical trial results (TOPAZ-1). Reduced efficacy was noted in patients with GB-CA and/or a reduced performance status that warrants further ...